Overview of phase 3 EMERALD study of elacestrant for ER+, HER2- MBC

Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the phase 3 EMERALD study that evaluated the efficacy of elacestrant as a second-line treatment for ER+, HER2- MBC, particularly in patients with tumors harboring an ESR1 mutation.

Now Viewing

EP: 1.Overview of phase 3 EMERALD study of elacestrant for ER+, HER2- MBC

EP: 2.Episode 2: Incidence of ESR1 mutations and best practices for testing

EP: 3.Co-occurrence of ESR1 mutations with other alterations

EP: 4.Elacestrant as second-line therapy for ESR1-mutated, endocrine-sensitive disease

EP: 5.EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease

EP: 6.Elacestrant: Clinical Pearls for Adverse Effect Management

EP: 7.Emerging data on oral selective estrogen receptor degraders

Recent Videos